Dehong Yang

Dr. Dehong Yang


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Bone
Verified
Journal Article
Open access
YMYangyang Ma
Yangyang Ma
XWXiaoliang Wu
Xiaoliang Wu
XXXiao Xiao
Xiao Xiao
YMYao Ma
Yao Ma
LFLan Feng
Lan Feng
DYDehong Yang
Dehong Yang
Osteoporotic vertebral compression fracture (OVCF) is a common disease in senior patients. Conservative treatments (usual care) and percutaneous vertebroplasty (PVP) are typically applied to treat OVCFs; however, their efficacies are not fully satisfactory. While Teriparatide (TPTD) is effective in both anti-osteoporosis and bone healing, whether TPTD could be applied as a conservative treatment for acute OVCFs remains unclear. This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice. TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day. A health survey (SF-36) was conducted at 0-, 1- and 3-months post-treatment. Back pain and the Oswestry Disability Index (ODI) were measured at 0-week, 1-week, 1-month and 3-months after treatment, while the direct medical cost was analyzed at the end of the third month. Both treatments with TPTD and PVP significantly and similarly improved the patients' health quality, with reduced visual analogue and ODI scores at the end of the first and third months. PVP was more effective in reducing pain at the early time point (1 week, p < 0.05). 24 of 27 patients who were rescanned with magnetic resonance imaging in the TPTD group showed bone healing. The mid-vertebral height was increased by PVP (p < 0.05) but not by TPTD. The cost of TPTD treatment was 21,868.61 ± 167.05 RMB per capita, while the cost for PVP treatment was 33,265.95 ± 1491.11 RMB per capita (p < 0.05). TPTD conservative treatment obtained similar therapeutic effects but cost less than PVP in terms of treating acute OVCF.

24 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXiaoyin Liu
Xiaoyin Liu
JMJinbiao Ma
Jinbiao Ma
YZYunrui Zhang
Yunrui Zhang
YXYi Xu
Yi Xu
YWYunxiao Wang
Yunxiao Wang
FZFenni Zhang
Fenni Zhang
Cellular glycosylation is crucial for cell recognition, signal transduction, and the development of various diseases, especially in tumor initiation, progression, and metastasis. Current glycosylation profiling methods normally involve laborious sample processing and labeling and lack in-situ quantitative analysis. Here, we present a direct optical method to investigate and quantify the glycan expression on single cells based on lectin-glycan kinetic quantification with plasmonic imaging. Three unlabeled lectins (WGA, SBA, ConA) are employed as probes to bind with specific glycans, and binding kinetics are assessed to determine glycosylation profiles. The result reveals cell-to-cell heterogeneity in glycosylation patterns. To demonstrate the capability of our method, the glycosylation profiling of four distinct cell lines is explored, showing obvious alterations in glycan expression related to tumor initiation, progression, and metastasis. This approach enables direct quantification of glycosylation and binding kinetics, providing insights into tumor cell glycosylation mechanisms and potential applications in disease diagnosis and treatment.

30 January 2025 in Advanced Science
Verified
Journal Article
Open access
XLXin Luo
Xin Luo
YZYanli Zhang
Yanli Zhang
YZYuting Zeng
Yuting Zeng
DYDehong Yang
Dehong Yang
ZZZhiyan Zhou
Zhiyan Zhou
WYWenjuan Yan
Wenjuan Yan
Oral diseases rank among the most prevalent clinical conditions globally, typically involving detrimental factors such as infection, inflammation, and injury in their occurrence, development, and outcomes. The concentration of reactive oxygen species (ROS) within cells has been demonstrated as a pivotal player in modulating these intricate pathological processes, exerting significant roles in restoring oral functionality and maintaining tissue structural integrity. Due to their enzyme‐like catalytic properties, unique composition, and intelligent design, ROS‐based nanomaterials have garnered considerable attention in oral nanomedicine. Such nanomaterials have the capacity to influence the spatiotemporal dynamics of ROS within biological systems, guiding the evolution of intra‐ROS to facilitate therapeutic interventions. This paper reviews the latest advancements in the design, functional customization, and oral medical applications of ROS‐based nanomaterials. Through the analysis of the components and designs of various novel nanozymes and ROS‐based nanoplatforms responsive to different stimuli dimensions, it elaborates on their impacts on the dynamic behavior of intra‐ROS and their potential regulatory mechanisms within the body. Furthermore, it discusses the prospects and strategies of nanotherapies based on ROS scavenging and generation in oral diseases, offering alternative insights for the design and development of nanomaterials for treating ROS‐related conditions.

17 April 2020 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
DYDehong Yang
Dehong Yang
YZYanlei Zhang
Yanlei Zhang
XMXiao Ma
Xiao Ma
LHLi Huo
Li Huo
LLLiran Li
Liran Li
YGYue Gao
Yue Gao
Background: Osteoporotic vertebral compression fractures (OVCF) is a common and often debilitating complication of osteoporosis, leading to significant morbidity and increased mortality. Percutaneous vertebroplasty (PVP) and Percutaneous kyphoplasty (PKP) are recommendable surgical treatments for OVCF. Objective: To evaluate PVP/PKP utilisation and their related direct medical costs for OVCF treatment in China from the payer perspective. Methods: A population-based medical claims database of a metropolitan city in China was analysed from the payer perspective, which included all inpatient claims from 01/01/2015 to 31/12/2017. All vertebral fractures patients that met the eligibility criteria (aged ≥50 years old, having vertebral fracture diagnosis, without unrelated diseases diagnoses such as tumour and scoliosis, received PVP/PKP) were deemed as OVCF patients. Baseline characteristics, surgery rate, length of stay in hospital, time to re-surgery, and costs (including costs per hospitalisation and annual costs) were described. Survival analysis function was used to estimate the re-surgery rate. Results: Of the 50,686 patients with OVCF identified, 14,527 (28.66%) received a total number of 15,599 records of PVP/PKP surgeries from 2015 to 2017. Mean age was 75 at the first surgery captured in the database analysis period; females accounted for 79.54% of all cases. The median length of surgery stay was 9 days. Cumulative re-surgery rates were 1.22% in 30 days, 2.58% in 90 days, 3.61% in 183 days, 5.42% in 1 year, and 7.95% in 2 years. There was no significant difference in re-surgery rate between PVP and PKP (p = 0.3897). The median time to the re-surgery was 139 days. Mean costs per PVP/PKP-related hospitalisation were 35,906 CNY/5122 USD (34,195 CNY/4878USD for PVP, 44,414 CNY/6336 USD for PKP, p < 0.01). The overall costs of hospitalisation averaged 186.61 million CNY (26.62 million USD) per year in this metropolitan city. Conclusion: From 2015 to 2017, nearly one-third of OVCF inpatients received PVP/PKP and the re-surgery rate was 7.95%. PVP/PKP procedures for OVCF place a high economic burden for both the healthcare system and patients. Early detection and treatment of patients with osteoporosis are critical in China.

11 November 2022 in Insect Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
YXYang Xu
Yang Xu
DCDongbin Chen
Dongbin Chen
SZShirui Zheng
Shirui Zheng
MYMeiyan Yi
Meiyan Yi
ZLZulian Liu
Zulian Liu
Yongping HuangYongping Huang
Yongping Huang

5 July 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
CZChunhao Zhou
Chunhao Zhou
ZCZhihai Cai
Zhihai Cai
JGJialiang Guo
Jialiang Guo
CLChengfu Li
Chengfu Li
CQChenghe Qin
Chenghe Qin
DYDehong Yang
Dehong Yang
Failed skin wound healing, through delayed wound healing or wound dehiscence, is a global public health issue that imposes significant burdens on individuals and society. Although the application of growth factor is an effective method to improve the pace and quality of wound healing, the clinically approved factors are limited. Parathyroid hormone (PTH) demonstrates promising results in wound healing by promoting collagen deposition and cell migration, but its application is limited by potentially inhibitory effects when administered continuously and locally. Through partially replacing and repeating the amino acid domains of PTH(1–34), we previously designed a novel PTH analog, PTH(3–34)(29–34) or MY-1, and found that it avoided the inhibitory effects of PTH while retaining its positive functions. To evaluate its role in wound healing, MY-1 was encapsulated in liposomes and incorporated into the methacryloyl gelatin (GelMA) hydrogel, through which an injectable nanocomposite hydrogel (GelMA–MY@Lipo, or GML) was developed. In vitro studies revealed that the GML had similar properties in terms of the appearance, microstructure, functional groups, swelling, and degradation capacities as the GelMA hydrogel. In vitro drug release testing showed a relatively more sustainable release of MY-1, which was still detectable in vivo 9 days post-application. When the GML was topically applied to the wound areas of rat models, wound closure as well as tensile strength were improved. Further studies showed that the effects of GML on wound repair and tensile strength were closely related to the promotion of fibroblast migration to the wound area through the controlled release of MY-1. Mechanically, MY-1 enhanced fibroblast migration by activating PI3K/AKT signaling and its downstream molecule, Rac1, by which it increased fibroblast aggregation in the early stage and resulting in denser collagen deposition at a later time. Overall, these findings demonstrated that the nanocomposite hydrogel system promoted skin wound healing and increased tensile strength, thus offering new potential in the treatment of wound healing.